TTOO vs. LYRA, STIM, KRMD, BLUA, BWAY, SRTS, HSAQ, ALUR, PDEX, and NVNO
Should you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include Lyra Therapeutics (LYRA), Neuronetics (STIM), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), and enVVeno Medical (NVNO). These companies are all part of the "surgical & medical instruments" industry.
Lyra Therapeutics (NASDAQ:LYRA) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.
T2 Biosystems received 384 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 64.65% of users gave T2 Biosystems an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
T2 Biosystems has higher revenue and earnings than Lyra Therapeutics.
95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are owned by institutional investors. 17.4% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 0.1% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
T2 Biosystems has a net margin of -636.09% compared to T2 Biosystems' net margin of -4,099.82%. Lyra Therapeutics' return on equity of 0.00% beat T2 Biosystems' return on equity.
Lyra Therapeutics currently has a consensus price target of $7.13, indicating a potential upside of 2,052.57%. T2 Biosystems has a consensus price target of $3.00, indicating a potential downside of 41.06%. Given T2 Biosystems' higher possible upside, research analysts plainly believe Lyra Therapeutics is more favorable than T2 Biosystems.
Lyra Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.
In the previous week, Lyra Therapeutics and Lyra Therapeutics both had 4 articles in the media. Lyra Therapeutics' average media sentiment score of 0.87 beat T2 Biosystems' score of 0.22 indicating that T2 Biosystems is being referred to more favorably in the news media.
Summary
Lyra Therapeutics and T2 Biosystems tied by winning 7 of the 14 factors compared between the two stocks.
Get T2 Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
T2 Biosystems Competitors List
Related Companies and Tools
